Voyager Therapeutics
VYGR
125 hedge funds and large institutions have $133M invested in Voyager Therapeutics in 2025 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 45 reducing their positions, and 8 closing their positions.
786% more call options, than puts
Call options by funds: $567K | Put options by funds: $64K
138% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 8
7% more funds holding
Funds holding: 117 → 125 (+8)
6.22% more ownership
Funds ownership: 54.47% → 60.69% (+6.2%)
6% less capital invested
Capital invested by funds: $141M → $133M (-$8.48M)
31% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$14.7M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$5.29M |
| 3 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
+$901K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$701K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$619K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.82M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1.11M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.07M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$904K |
| 5 |
AC
Armistice Capital
New York
|
-$885K |
VYGR Hedge Fund Activity: Q4 2025 in Review
125 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q4 2025, worth a combined $133M — down 6% from $141M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new VYGR positions and 8 closed out — a net gain of 11 holders — while 31 added to existing stakes and 45 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $14.7M. The largest seller was Millennium Management, cutting an estimated $1.82M.
- 125 institutional investors held Voyager Therapeutics (VYGR) as of Q4 2025, up from 117 in Q3 2025.
- Funds reported $133M of Voyager Therapeutics stock for Q4 2025, down 6% quarter-over-quarter.
- 19 funds opened new Voyager Therapeutics positions in Q4 2025 and 8 closed out, a net change of +11 holders.
- The largest Voyager Therapeutics buyer in Q4 2025 was EcoR1 Capital, an estimated $14.7M added.
- The largest Voyager Therapeutics seller in Q4 2025 was Millennium Management, an estimated $1.82M sold.
Based on aggregated 13F filings for Q4 2025.